Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3

Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was undertaken to evaluate the association of an increase in PR3‐ANCA level with subsequent relapse.

[1]  D. Metze,et al.  Nomenclature of cutaneous vasculitides – German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  Kenneth G. C. Smith,et al.  Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. , 2015, Rheumatology.

[3]  P. Merkel,et al.  Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids , 2015, Arthritis & rheumatology.

[4]  U. Specks.  Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail. , 2015, Journal of the American Society of Nephrology : JASN.

[5]  P. van Paassen,et al.  ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. , 2015, Journal of the American Society of Nephrology : JASN.

[6]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[7]  M. Resche-Rigon,et al.  Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. , 2014, Autoimmunity reviews.

[8]  M. Mahler,et al.  Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. , 2013, Autoimmunity reviews.

[9]  P. Merkel,et al.  Efficacy of remission-induction regimens for ANCA-associated vasculitis. , 2013, The New England journal of medicine.

[10]  Yali Cao,et al.  Predictors of Treatment Resistance and Relapse in Chinese Patients with Antineutrophil Cytoplasmic Antibody-associated Disease , 2013, The Journal of Rheumatology.

[11]  C. Langford.  Clinical features and diagnosis of small-vessel vasculitis , 2012, Cleveland Clinic Journal of Medicine.

[12]  T. Peikert,et al.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. , 2012, Arthritis and rheumatism.

[13]  Yichun Hu,et al.  Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. , 2012, Arthritis and rheumatism.

[14]  C. Alpers,et al.  Anti-Proteinase 3 Anti-Neutrophil Cytoplasm Autoantibodies Recapitulate Systemic Vasculitis in Mice with a Humanized Immune System , 2012, PloS one.

[15]  G. Sebastiani,et al.  [Antineutrophil cytoplasmic antibodies]. , 2011, Reumatismo.

[16]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[17]  W. Goldmann,et al.  Anti‐PR3 immune responses induce segmental and necrotizing glomerulonephritis , 2010, Clinical and experimental immunology.

[18]  J. Piette,et al.  Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides , 2008, Annals of the rheumatic diseases.

[19]  P. van Paassen,et al.  A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis , 2008, Annals of the rheumatic diseases.

[20]  D. Schroeder,et al.  Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis , 2007, Annals of Internal Medicine.

[21]  Augustine S. Lee,et al.  ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. , 2007, The American journal of medicine.

[22]  C. Kallenberg,et al.  Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. , 2006, Rheumatology.

[23]  Jianwen Cai,et al.  Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.

[24]  P. Merkel,et al.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). , 2005, Arthritis and rheumatism.

[25]  Hyon K. Choi,et al.  Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. , 2003, Kidney international.

[26]  J. Wieslander,et al.  Relationship between anti‐neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long‐term clinical course in vasculitis , 2002, Journal of internal medicine.

[27]  F. J. van der Woude,et al.  ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  M. Daha,et al.  Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. , 2001, Journal of the American Society of Nephrology : JASN.

[29]  P. Merkel,et al.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). , 2001, Arthritis and rheumatism.

[30]  M. André,et al.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. , 2001, Rheumatology.

[31]  P. Limburg,et al.  Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. , 2000, Arthritis and rheumatism.

[32]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[33]  E. Hachulla,et al.  Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. , 1999, The American journal of medicine.

[34]  C. Franssen,et al.  Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti‐proteinase 3 and anti‐myeloperoxidase autoantibodies , 1998, Journal of internal medicine.

[35]  A. Wiik,et al.  Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. , 1998, Kidney international.

[36]  U. Specks,et al.  Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. , 1998, Journal of immunological methods.

[37]  C. Pusey,et al.  ANCA and predicting relapse in systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.

[38]  C. Hallahan,et al.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. , 1993, Arthritis and rheumatism.

[39]  E. Pettersson,et al.  Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. , 1992, Clinical nephrology.

[40]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[41]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[42]  T. The,et al.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.

[43]  R J Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Kallenberg,et al.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.

[45]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[46]  A. Wiik,et al.  Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity. , 2013, Clinical and experimental rheumatology.

[47]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[48]  P. Merkel,et al.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.

[49]  R. Panush.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .

[50]  W. Kremers,et al.  Concordance for Survival Time Data: Fixed and Time-Dependent Covariates and Possible Ties in Predictor and Time , 2007 .

[51]  F. J. van der Woude,et al.  Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[53]  B. Thiers.  Etanercept plus standard therapy for Wegener's granulomatosis. , 2005, The New England journal of medicine.

[54]  C. Kallenberg,et al.  Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.

[55]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.